875 Chorismate synthase, AroC
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Mixed metal/non-metal compounds | 1 | 0.1 | 8.05× | not tested | |
| Homogeneous non-metal compounds | 3 | 1.3 | 2.36× | not tested | |
| Nucleosides, nucleotides, and analogues | 3 | 1.6 | 1.83× | not tested | |
| Organoheterocyclic compounds | 1 | 0.9 | 1.10× | not tested | |
| Organic acids and derivatives | 1 | 0.9 | 1.09× | not tested | |
| Organic oxygen compounds | 1 | 1.2 | 0.85× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03247 | FMN | Flavin mononucleotide | 9 |
| DB03350 | NCO | Cobalt hexammine ion | 4 |
| DB09459 | TLA | L-tartaric acid | 2 |
| DB02701 | NCA | Nicotinamide | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| FMN | FLAVIN MONONUCLEOTIDE | 9 |
| CL | CHLORIDE ION | 4 |
| EPS | 5-[(1-CARBOXYVINYL)OXY]-4-HYDROXY-3-(PHOSPHONOOXY)CYCLOHEX-1-ENE-1-CARBOXYLIC ACID | 4 |
| NCO | COBALT HEXAMMINE(III) | 4 |
| NAmetal | SODIUM ION | 3 |
| TLA | L(+)-TARTARIC ACID | 2 |
| NCA | NICOTINAMIDE | 1 |